Detalles de la búsqueda
1.
A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines.
Mol Cancer Ther
; 8(4): 771-8, 2009 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-19372549
2.
Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer.
Mol Cancer Ther
; 8(1): 194-202, 2009 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-19139129
3.
Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy.
Int J Cancer
; 124(12): 2905-10, 2009 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19296535
4.
Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer.
Eur J Cancer
; 44(9): 1229-37, 2008 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-18448328
5.
PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.
PLoS One
; 10(5): e0123830, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25955657
6.
Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance.
Mol Cancer Ther
; 14(8): 1767-76, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26184483
Resultados
1 -
6
de 6
1
Próxima >
>>